Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Clinical Oncology

• Publication date

  1997-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1997.15.3.955PMID 9060533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

  1996cited by this paper
• Estrogen Replacement Therapy in Survivors of Breast Cancer

  1996cited by this paper
• Tamoxifen: oestrogen or anti-oestrogen in bone?

  1995cited by this paper
• The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

  1995cited by this paper
• Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

  1995cited by this paper
• Urinary excretion of deoxypyridinoline in patients with breast cancer.

  1995cited by this paper
• Bisphosphonates in the treatment of disorders of mineral metabolism.

  1995cited by this paper
• Management of menopause in women with breast cancer.

  1995cited by this paper
• When tamoxifen turns bad.

  1995cited by this paper
• Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.

  1995cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Influence of early age at menopause on vertebral bone mass

  1994cited by this paper
• Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.

  1994cited by this paper
• Pathogenesis of vertebral crush fractures in women.

  1994cited by this paper
• Bisphosphonates : Structure-Activity Relationships and Therapeutic Implications

  1994cited by this paper
• Nonhormonal alternatives for the management of early menopause in younger women with breast cancer.

  1994cited by this paper
• A Risk-Benefit Assessment of Tamoxifen Therapy

  1993cited by this paper
• Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry.

  1993cited by this paper
• Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.

  1993cited by this paper
• Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast

  1993cited by this paper
• Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.

  1992cited by this paper
• Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause

  1992cited by this paper
• Risk for developing osteoporosis in untreated premature menopause

  1992cited by this paper
• Estrogen and diphosphonate treatment provide long‐term protection against osteopenia in ovariectomized rats

  1991cited by this paper
• Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.

  1990cited by this paper
• Antiresorptive dose-response relationships across three generations of bisphosphonates.

  1989cited by this paper
• Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis.

  1987cited by this paper

• Effectiveness and safety of bone protective interventions to mitigate bone loss and skeletal fractures experienced by patients with non-metastatic breast cancer: a systematic review and meta-analysis.

  2026cites this paper
• Impact of Endocrine Therapy on Osteoporosis Risk in Women with Breast Cancer Across Different Hormonal Stages: A Review

  2025cites this paper
• Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies.

  2024cites this paper
• The Bone, Exercise, Alendronate, and Caloric Restriction (BEACON) trial design and methods.

  2024cites this paper
• Development and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer

  2024cites this paper
• Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.

  2024cites this paper
• Advances in the care of breast cancer survivors

  2023cites this paper
• Bone health in breast cancer.

  2023cites this paper
• Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer

  2023cites this paper
• Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis

  2022cites this paper
• Osteoporosis in premenopausal women.

  2021cites this paper
• Breast cancer therapy and bone

  2021cites this paper
• Risedronate use to attenuate bone loss following sleeve gastrectomy: Results from a pilot randomized controlled trial

  2021cites this paper
• Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

  2020cites this paper
• Bisphosphonates and breast cancer survival: a meta-analysis and trial sequential analysis of 81508 participants from 23 prospective epidemiological studies

  2020cites this paper
• Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures

  2020cites this paper
• History of risedronate.

  2020cites this paper
• Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l’ostéoporose induite par les traitements adjuvants du cancer du sein

  2019influential citation
• French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

  2019cites this paper
• Cancer Treatment-Induced Bone Loss (CTIBL)

  2019cites this paper
• Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study

  2019influential citation
• A microbiological study of medication-related osteonecrosis of the jaw (MRONJ) and actinomyces involvement in the disease

  2018cites this paper
• Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

  2018cites this paper
• Bone-Targeted Therapy in Early Breast Cancer

  2018cites this paper
• A Clinical Review

  2017cites this paper
• Effect of Adjuvant (Hormonal) Therapy on Bone Mineral Density in Caucasian Women with Breast Cancer

  2017cites this paper
• Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment.

  2017cites this paper
• Bisphosphonates and other bone agents for breast cancer.

  2017cites this paper
• Salivary biomarkers to monitor osteopenia and stress levels in breast cancer survivors

  2017cites this paper
• Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

  2016cites this paper
• Elevated incidence of fractures in women with invasive breast cancer

  2016cites this paper
• Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients

  2016cites this paper
• Aromatase inhibitor treatment for breast cancer: short-term effect on bone health

  2015cites this paper
• Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

  2015cites this paper
• Adjuvant Endocrine Therapy and Bone Health in Breast Cancer

  2015influential citation
• Bisphosphonates in breast cancer

  2015cites this paper
• Pathophysiologie und Behandlung der therapieinduzierten Osteoporose

  2014cites this paper
• The effect of systemically and locally administered clodronate on bone quality

  2014cites this paper
• Differentiation of PC12 cells expressing estrogen receptor alpha: a new bioassay for endocrine-disrupting chemicals evaluation.

  2014cites this paper
• The key role of bisphosphonates in the supportive care of cancer patients.

  2014cites this paper
• A Review of Osteoporosis Management in Younger Premenopausal Women

  2014cites this paper
• Moderne Osteoprotektion in der Onkologie

  2014cites this paper
• Task Force Report : Bone Health in Cancer Care

  2013cites this paper
• Exercise and Cancer

  2013cites this paper
• 63. Premenopausal Osteoporosis

  2013cites this paper
• Cancer-associated bone disease

  2013cites this paper
• NCCN Task Force Report: Bone Health In Cancer Care.

  2013cites this paper
• Bone mineral density following surgical oophorectomy and tamoxifen adjuvant therapy for breast cancer

  2013cites this paper
• Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

  2013cites this paper
• Cancer Treatment-Induced Bone Loss in Patients with Breast Cancer: Pathophysiology and Clinical Perspectives

  2013cites this paper
• Bone Homeostasis and Breast Cancer: Implications for Complex Therapy and the Maintenance of Bone Integrity

  2012cites this paper
• Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease

  2012cites this paper
• The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma

  2012cites this paper
• A meta-analysis characterizing the dose–response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women

  2012cites this paper
• The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer

  2012cites this paper
• Osteoporosis in young adults: pathophysiology, diagnosis, and management

  2012cites this paper
• Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

  2012cites this paper
• Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.

  2012cites this paper
• Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy—Effect on Survival: A Systematic Review and Meta-Analysis

  2012cites this paper
• Bone health in adult cancer survivorship.

  2012cites this paper
• Bisphosphonates and other bone agents for breast cancer.

  2012cites this paper
• A prospective model of care for breast cancer rehabilitation: Bone health and arthralgias

  2012cites this paper
• Denosumab and the current status of bone-modifying drugs in breast cancer

  2012cites this paper
• Effect of anastrozole on bone mineral density and lipid profiles when used to prevent breast cancer in high risk postmenopausal women

  2012cites this paper
• Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid

  2012cites this paper
• Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors.

  2011cites this paper
• Can we predict who's at risk for developing bone metastases in breast cancer?

  2011cites this paper
• Metastatic/Myeloma Disease—Nonoperative Management

  2011cites this paper
• Advances in management of bone disease in breast cancer.

  2011cites this paper
• Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer

  2011cites this paper
• Dosing of zoledronic acid throughout the treatment continuum in breast cancer.

  2011cites this paper
• 42 – Bone health and prevention of treatment-induced osteoporosis in oncology

  2011cites this paper
• The use of bisphosphonates in cancer treatment

  2011cites this paper
• Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease.

  2011cites this paper
• Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases

  2010cites this paper
• Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis.

  2010cites this paper
• The role of bisphosphonates in the adjuvant setting for breast cancer.

  2010cites this paper
• Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

  2010cites this paper
• [Bisphosphonates in adjuvant therapy of breast cancer].

  2010cites this paper
• Zoledronic Acid: Its Use in the Treatment of Breast Cancer

  2010cites this paper
• Bisphosphonates, Bone Health and the Clinical Biology of Bone Metastases from Breast Cancer

  2010cites this paper
• Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

  2010cites this paper
• The evolving role of bone-conserving therapy in patients with breast cancer.

  2010cites this paper
• Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials.

  2010cites this paper
• Understanding and Optimizing Bone Health in Breast Cancer

  2010cites this paper
• Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.

  2010cites this paper
• 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

  2010cites this paper
• Emerging drugs for the management of cancer treatment induced bone loss

  2010cites this paper
• Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)

  2010influential citation
• Bisphosphonates: ready for use as adjuvant therapy of breast cancer?

  2010cites this paper
• Bisphosphonate in der adjuvanten Therapie des Mammakarzinoms

  2010cites this paper
• Bone Disease in Breast Cancer: The Era of New Targeted Therapies

  2010cites this paper
• Current and emerging treatment strategies for breast cancer-induced bone loss.

  2010cites this paper
• Biphosphonates In The Management Of Metastatic Bone Disease

  2009cites this paper
• Update on identifying and managing osteoporosis in women with breast cancer.

  2009cites this paper
• New results from the use of bisphosphonates in cancer patients

  2009cites this paper
• Management of complications from estrogen deprivation in breast cancer patients

  2009cites this paper
• Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?

  2009cites this paper
• Putting evidence into practice: prevention and management of bleeding in patients with cancer.

  2009cites this paper
• Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

  2009cites this paper